Omalizumab for atopic dermatitis: case series and a systematic review of the literature

Publikation: Bidrag til tidsskriftReviewForskningfagfællebedømt

Standard

Omalizumab for atopic dermatitis : case series and a systematic review of the literature. / Holm, Jesper Grønlund; Agner, Tove; Sand, Carsten; Thomsen, Simon Francis.

I: International Journal of Dermatology, Bind 56, Nr. 1, 01.2017, s. 18-26.

Publikation: Bidrag til tidsskriftReviewForskningfagfællebedømt

Harvard

Holm, JG, Agner, T, Sand, C & Thomsen, SF 2017, 'Omalizumab for atopic dermatitis: case series and a systematic review of the literature', International Journal of Dermatology, bind 56, nr. 1, s. 18-26. https://doi.org/10.1111/ijd.13353

APA

Holm, J. G., Agner, T., Sand, C., & Thomsen, S. F. (2017). Omalizumab for atopic dermatitis: case series and a systematic review of the literature. International Journal of Dermatology, 56(1), 18-26. https://doi.org/10.1111/ijd.13353

Vancouver

Holm JG, Agner T, Sand C, Thomsen SF. Omalizumab for atopic dermatitis: case series and a systematic review of the literature. International Journal of Dermatology. 2017 jan;56(1):18-26. https://doi.org/10.1111/ijd.13353

Author

Holm, Jesper Grønlund ; Agner, Tove ; Sand, Carsten ; Thomsen, Simon Francis. / Omalizumab for atopic dermatitis : case series and a systematic review of the literature. I: International Journal of Dermatology. 2017 ; Bind 56, Nr. 1. s. 18-26.

Bibtex

@article{cda591ec43c245d8921082c266d72e01,
title = "Omalizumab for atopic dermatitis: case series and a systematic review of the literature",
abstract = "Omalizumab is a recombinant humanized monoclonal antibody targeting the high-affinity Fc receptor of IgE, registered for the treatment of chronic spontaneous urticaria and severe allergic asthma. We present a case series of nine patients with atopic dermatitis (AD) treated off-label with omalizumab and a systematic review of the existing literature. Patients were selected consecutively from a tertiary dermatological referral center during a 5-year period. All patients were treated with omalizumab at a starting dose of 300 mg subcutaneously every 4 weeks. Systematic literature searches were performed in PubMed, Web of Science, EMBASE, and ClinicalTrials.gov to identify any study (case reports, case series, and controlled trials) evaluating the effect of treatment with omalizumab in AD. Based on physicians' assessment, 50% of our patients had a good or excellent response to treatment with omalizumab; a further 12.5% had a moderate response, while 37.5% experienced no response or deterioration of symptoms during treatment. Treatment was generally well tolerated. Twenty-six studies with a median of four patients each (range 1-21), comprising 174 patients, were included in the systematic review. Summed over all studies, a total of 129 patients (74.1%) experienced a beneficial effect of treatment ranging from little to complete response. Omalizumab appears to be a safe and well tolerated, however expensive, treatment with some clinical benefit in patients with severe recalcitrant AD. Recommendation for use in clinical practice awaits evidence from larger randomized controlled trials.",
keywords = "Adult, Aged, Anti-Allergic Agents, Dermatitis, Atopic, Female, Humans, Male, Middle Aged, Off-Label Use, Omalizumab, Treatment Outcome, Young Adult, Journal Article, Review",
author = "Holm, {Jesper Gr{\o}nlund} and Tove Agner and Carsten Sand and Thomsen, {Simon Francis}",
note = "{\textcopyright} 2016 The International Society of Dermatology.",
year = "2017",
month = jan,
doi = "10.1111/ijd.13353",
language = "English",
volume = "56",
pages = "18--26",
journal = "International Journal of Dermatology",
issn = "0011-9059",
publisher = "Wiley-Blackwell",
number = "1",

}

RIS

TY - JOUR

T1 - Omalizumab for atopic dermatitis

T2 - case series and a systematic review of the literature

AU - Holm, Jesper Grønlund

AU - Agner, Tove

AU - Sand, Carsten

AU - Thomsen, Simon Francis

N1 - © 2016 The International Society of Dermatology.

PY - 2017/1

Y1 - 2017/1

N2 - Omalizumab is a recombinant humanized monoclonal antibody targeting the high-affinity Fc receptor of IgE, registered for the treatment of chronic spontaneous urticaria and severe allergic asthma. We present a case series of nine patients with atopic dermatitis (AD) treated off-label with omalizumab and a systematic review of the existing literature. Patients were selected consecutively from a tertiary dermatological referral center during a 5-year period. All patients were treated with omalizumab at a starting dose of 300 mg subcutaneously every 4 weeks. Systematic literature searches were performed in PubMed, Web of Science, EMBASE, and ClinicalTrials.gov to identify any study (case reports, case series, and controlled trials) evaluating the effect of treatment with omalizumab in AD. Based on physicians' assessment, 50% of our patients had a good or excellent response to treatment with omalizumab; a further 12.5% had a moderate response, while 37.5% experienced no response or deterioration of symptoms during treatment. Treatment was generally well tolerated. Twenty-six studies with a median of four patients each (range 1-21), comprising 174 patients, were included in the systematic review. Summed over all studies, a total of 129 patients (74.1%) experienced a beneficial effect of treatment ranging from little to complete response. Omalizumab appears to be a safe and well tolerated, however expensive, treatment with some clinical benefit in patients with severe recalcitrant AD. Recommendation for use in clinical practice awaits evidence from larger randomized controlled trials.

AB - Omalizumab is a recombinant humanized monoclonal antibody targeting the high-affinity Fc receptor of IgE, registered for the treatment of chronic spontaneous urticaria and severe allergic asthma. We present a case series of nine patients with atopic dermatitis (AD) treated off-label with omalizumab and a systematic review of the existing literature. Patients were selected consecutively from a tertiary dermatological referral center during a 5-year period. All patients were treated with omalizumab at a starting dose of 300 mg subcutaneously every 4 weeks. Systematic literature searches were performed in PubMed, Web of Science, EMBASE, and ClinicalTrials.gov to identify any study (case reports, case series, and controlled trials) evaluating the effect of treatment with omalizumab in AD. Based on physicians' assessment, 50% of our patients had a good or excellent response to treatment with omalizumab; a further 12.5% had a moderate response, while 37.5% experienced no response or deterioration of symptoms during treatment. Treatment was generally well tolerated. Twenty-six studies with a median of four patients each (range 1-21), comprising 174 patients, were included in the systematic review. Summed over all studies, a total of 129 patients (74.1%) experienced a beneficial effect of treatment ranging from little to complete response. Omalizumab appears to be a safe and well tolerated, however expensive, treatment with some clinical benefit in patients with severe recalcitrant AD. Recommendation for use in clinical practice awaits evidence from larger randomized controlled trials.

KW - Adult

KW - Aged

KW - Anti-Allergic Agents

KW - Dermatitis, Atopic

KW - Female

KW - Humans

KW - Male

KW - Middle Aged

KW - Off-Label Use

KW - Omalizumab

KW - Treatment Outcome

KW - Young Adult

KW - Journal Article

KW - Review

U2 - 10.1111/ijd.13353

DO - 10.1111/ijd.13353

M3 - Review

C2 - 27337170

VL - 56

SP - 18

EP - 26

JO - International Journal of Dermatology

JF - International Journal of Dermatology

SN - 0011-9059

IS - 1

ER -

ID: 183159427